Physicians' Academy for Cardiovascular Education

siRNA therapy and LDL-C

Follow news on the evolving field of siRNA therapy and lowerting of LDL-c

Novel RNAi therapeutic lowers blood pressure in patients with hypertension

3' education - Nov. 13, 2023 - George Bakris, MD

PCSK9i: Benefits across the spectrum of cardiovascular disease

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD

Large study assessing long-term efficacy and safety of PCSK9 siRNA

3' education - Sep. 4, 2023 - R. Scott Wright, MD

4-year follow-up data on efficacy and safety of PCSK9 siRNA

5' education - May 8, 2023 - Kausik Ray, MD

Guidance for an individualized statin intolerance approach

5' education - Jan. 30, 2023 - Prof. Maciej Banach, MD, PhD

Targeting the PCSK9 pathway: where do novel therapies fit in?

10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD

Changing paradigms in LDL-c reduction

10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD - Online CME
Experts in dialogue - LDL-c goal attainment in high risk patients

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME

PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c

3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia

Targeting PCSK9: Expanding knowledge and targeting new frontiers

10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD

LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial

10' education - Sep. 16, 2019 - Prof. John Kastelein

Targeting PCSK9 in clinical practice: Guidance & future

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME

LDL lowering versus LDL eradication; what makes clinical sense ?

10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands

LDL-c still reduced after 1 year with siRNA against PCSK9

3' education - Aug. 28, 2017

LDL lowering for CVD prevention: From hypothesis to axiom

10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA

siRNA targeting TTR improves functional capacity in ATTR cardiac amyloidosis

Literature - Nov. 20, 2023 - Maurer MS, et al. - N Engl J Med. 2023

In the APOLLO-B trial, 12-month treatment with patisiran resulted in preserved functional capacity, health status, and quality of life in patients with transthyretin (ATTR) cardiac amyloidosis compared with placebo.

Phase 3 trial does not confirm efficacy of PCSK9 siRNA in HoFH

Literature - Nov. 20, 2023 - Raal F, et al. - Circulation. 2023

The ORION-5 trial, in which 56 patients with homozygous familial hypercholesterolemia (HoFH) were treated with inclisiran or placebo, did not meet its primary endpoint of LDL-c reduction at 150 days. The PCSK9 level did decrease in the inclisiran group.

Phase 1 trial results of extended duration siRNA targeting Lp(a)

News - Nov. 14, 2023

AHA 2023 In a placebo-controlled phase 1 trial, a single dose of lepodisiran reduced Lp(a) level in a dose-dependent manner (up to 94% at 48 weeks) in individuals with elevated Lp(a) levels. The therapeutic was well-tolerated.

Novel RNAi therapeutic lowers blood pressure in patients with hypertension

3' education - Nov. 13, 2023 - George Bakris, MD
**AHA 2023** George Bakris shares the results of the KARDIA-1 trial, in which zilebesiran, a RNAi therapeutic targeting angiotensinogen, lowers blood pressure for up to 6 months with a single subcutaneous injection.

AHA 2023 George Bakris shares the results of the KARDIA-1 trial, in which zilebesiran, a RNAi therapeutic targeting angiotensinogen, lowers blood pressure for up to 6 months with a single subcutaneous injection.

Angiotensinogen RNAi therapeutic lowers SBP up to 6 months in patients with hypertension

News - Nov. 13, 2023

AHA 2023 In the phase 2 KARDIA-1 trial, a single dose of the RNA interference therapeutic zilebesiran led to reductions in 24-h ambulatory systolic BP at month 3 in patients with hypertension, and these effects were sustained over 6 months.

PCSK9i: Benefits across the spectrum of cardiovascular disease

10' education - Oct. 16, 2023 - Fabrice Martens, MD, PhD
Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.

Good risk stratification and optimal LDL-c lowering are key elements in treating patients at high CV risk. Fabrice Martens gives an overview of the effects of PCSK9i in lowering LDL-c and CV risk.

Phase 2 study of siRNA targeting angiotensinogen in patients with hypertension meets primary endpoint

News - Sep. 11, 2023

The KARDIA 1 phase 2 trial showed a reduction in 24-h ambulatory systolic BP of greater than 15 mmHg with the two highest single doses of the siRNA therapeutic zilebesiran, targeting hepatic angiotensinogen synthesis, at month 3 compared with placebo.

Long-term efficacy and safety data of PCSK9 siRNA in patients with high CV risk and elevated LDL-c

News - Sep. 4, 2023

ESC Congress 2023 The ORION-8 trial, an open-label extension of ORION-3/9/10/11, demonstrated the efficacy, safety and tolerability of inclisiran in patients with high cardiovascular risk and elevated LDL-c.

Large study assessing long-term efficacy and safety of PCSK9 siRNA

3' education - Sep. 4, 2023 - R. Scott Wright, MD
**ESC Congress 2023** In ORION-8, long-term efficacy and safety of the PCSK9 siRNA inclisiran was assessed in a large patient population with high CV risk. R. Scott Wright shares the results.

ESC Congress 2023 In ORION-8, long-term efficacy and safety of the PCSK9 siRNA inclisiran was assessed in a large high CV risk patient population. R. Scott Wright shares the results.

Phase 1 study with siRNA targeting hepatic angiotensinogen synthesis in patients with hypertension

Literature - Aug. 24, 2023 - Desai AS, et al. - N Engl J Med. 2023

In a phase 1 study, a single dose of the siRNA zilebesiran reduced serum angiotensinogen levels and blood pressure in patients with hypertension up to 24 weeks.

New guideline for chronic coronary disease

Literature - July 25, 2023 - Virani SS et al. - Circulation. 2023

The 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease has been published.

FDA approves expanded indication for PCSK9 siRNA for primary prevention

News - July 11, 2023

The FDA has approved expanded indication for inclisiran, enabling broader use of inclisiran in patients with primary hyperlipidemia with increased CV risk, but who have not had a CV event.